Sign in Subscribe
Biological products

Kivu Bioscience Presents Promising Preclinical Data for KIVU-107 ADC at 16th World ADC San Diego

Strategic Insights

— 1 min read

Kivu Bioscience, a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, has announced the presentation of new preclinical activity and safety data for KIVU-107, a best-in-class PTK7-targeting ADC, at the 16th World ADC San Diego conference. The data highlight the unique biophysical and therapeutic properties of KIVU-107, showcasing its potential to set a new standard among next-generation ADCs.

Key Takeaways:

  • KIVU-107 is a PTK7-targeting ADC engineered with exceptional stability and highly selective on-tumor delivery, leveraging DAR4 exatecan payload technology.
  • Preclinical data demonstrate deeper and durable anti-tumor activity across multiple xenograft models, with a wide therapeutic index and well-tolerated profile in repeat-dose GLP studies.
  • Repeat-dose GLP toxicology studies in non-human primates demonstrated favorable pharmacokinetics, minimal unconjugated exatecan exposure, and an exceptional tolerability profile supporting a potential higher starting dose for first-in-human evaluation.
  • Potent antigen-specific cytotoxicity was observed with rapid internalization in vitro and in mouse xenograft models, with durable complete tumor regressions after a single dose.
  • KIVU-107 showed robust activity in combination with olaparib and in ADC-resistant patient-derived xenograft models, supporting its potential to overcome resistance mechanisms seen with current ADC therapies.
  • The preclinical data collectively demonstrate that KIVU-107 combines precision targeting with a potent and controllable payload, resulting in a differentiated ADC profile with a remarkably wide therapeutic index.
  • Kivu Bioscience will initiate a Phase 1 clinical study of KIVU-107, a PTK7-targeting ADC, this quarter.

Statistics:

  • 16th World ADC San Diego conference presentation date: November 3-6, 2025
  • Number of xenograft models: multiple
  • Dose range: Not specified
  • Exatecan payload: DAR4 configuration
  • Repeat-dose GLP toxicology studies: Conducted in non-human primates
  • Number of poster presentations: 1
  • Session: Day 2 Poster Session
  • Date/time: Wednesday, November 5, 8 AM - 6 PM PT

Sources:

  • Kivu Bioscience press release, October 20, 2025, announcing presentation of KIVU-107 data at the 16th World ADC San Diego conference
  • 16th World ADC San Diego conference program, November 3-6, 2025
  • Businesswire.com, Kivu Bioscience to Present New Preclinical Data for KIVU-107 ADC at 16th World ADC San Diego, October 20, 2025.

Read more